• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Rep . Metabolomic and clinical feature analyses of plasma from influenza A patients

tetano

Editor, Senior Moderator
Sci Rep


. 2025 Nov 28;15(1):42616.
doi: 10.1038/s41598-025-26805-4. Metabolomic and clinical feature analyses of plasma from influenza A patients

Yaping Li[SUP] #[/SUP][SUP] 1 [/SUP], Ting Li[SUP] #[/SUP][SUP] 1 [/SUP], Min Liu[SUP] 1 2 [/SUP], XinYu Wang[SUP] 1 [/SUP], Song Zhai[SUP] 1 [/SUP], Ruihong Qin[SUP] 3 [/SUP], Chenrui Liu[SUP] 1 [/SUP], Yuanyi Chen[SUP] 1 [/SUP], Meng Zhang[SUP] 1 [/SUP], Xiaoli Jia[SUP] 4 [/SUP]



Affiliations
Abstract

Plasma metabolomics offers valuable insights for identifying viral infection biomarkers with applications in early diagnosis, outcome prediction, and treatment monitoring. This study aimed to investigate metabolomic alterations in influenza A patients and identify potential biomarkers for disease severity. From March 2023 to March 2024, 339 influenza A patients were enrolled. After age‒sex matching, 54 patients and 20 healthy controls were selected for analysis. Untargeted metabolomic profiling of 74 plasma samples was conducted using ultrahigh-performance liquid chromatography coupled with tandem mass spectrometry. Comparative analysis revealed 60 differentially expressed metabolites between H1N1 patients and healthy controls, with 41 significantly upregulated and 19 downregulated. Pathway enrichment analysis revealed prominent disruptions in glycerophospholipid metabolism, with several metabolites showing alterations across the severity spectrum. Amino acid metabolism, particularly propionate metabolism, glycine-serine-threonine metabolism, and branched-chain amino acid biosynthesis, was also notably disturbed. Critical exhibited marked disturbances in taurine-hypotaurine metabolism compared to milder. This study identified glycerophospholipid metabolism dysregulation as a potential biomarker for influenza severity stratification. The progressive alteration of taurine pathway metabolites in critical suggests their pivotal role in severe H1N1 pathogenesis, highlighting their dual potential as diagnostic biomarkers and therapeutic targets.

Keywords: Glycerophospholipids; Influenza A (H1N1); Metabolic profiling; Severity biomarkers; Taurine metabolism.

 
Back
Top